Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

A Mayer*, 1, SK Sharma, B Tolner, NP Minton, D Purdy, P Amlot, 2, G Tharakan, RHJ Begent, 1 and KA Chester

1Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, UK; 2Department of Immunology, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, UK; 3Institute of Infections, Immunity and Inflammation, University of Nottingham, Floor C, West Block, Queens Medical Centre, Nottingham NG7 2UH, UK; 4Health Protection Agency, Porton Down, Salisbury, Wiltshire SP4 0JG, UK

Carboxypeptidase G2 (CP) is a bacterial enzyme, which is targeted to tumours by an antitumour antibody for local prodrug activation in antibody-directed enzyme prodrug therapy (ADEPT). Repeated cycles of ADEPT are desirable but are hampered by human antibody response to CP (HACA). To address this, we aimed to identify and modify clinically important immunogenic sites on MFECF, a recombinant fusion protein of CP with MFE-23, a single Fv (scFv) antibody. A discontinuous conformational epitope at the C-terminus of the CP previously identified by the CM79 scFv antibody (CM79-identified epitope) was chosen for study. Modification of MFECF was achieved by mutations of the CM79-identified epitope or by addition of a hexahistidine tag (His-tag) to the C-terminus of MFECF, which forms part of the epitope. Murine immunisation experiments with modified MFECF showed no significant antibody response to the CM79-identified epitope compared to A5CP, an unmodified version of CP chemically conjugated to an F(ab)2 antibody. Success of modification was also demonstrated in humans because patients treated with His-tagged MFECF had a significantly reduced antibody response to the CM79-identified epitope, compared to patients given A5CP. Moreover, the polyclonal antibody response to CP was delayed in both mice and patients given modified MFECF. This increases the prospect of repeated treatment with ADEPT for effective cancer treatment.

British Journal of Cancer (2004) 90, 2402 – 2410. doi:10.1038/sj.bjc.6601888 www.bjcancer.com

© 2004 Cancer Research UK

Keywords: ADEPT; immunogenicity; carboxypeptidase G2; antibody response

Antibody-directed enzyme prodrug therapy (ADEPT) is an experimental cancer treatment in which an antibody linked either chemically or genetically to tumour-targeting antibody is given intravenously. When the antibody–enzyme has cleared from the circulation, a prodrug is given and is converted to active drug in the tumour by the targeted enzyme (Bagshawe et al., 1988). An illustration of the ADEPT concept is shown in Figure 1. ADEPT aims to overcome the shortcomings of systemic cancer treatment such as lack of tumour selectivity and drug resistance. Clinical ADEPT studies (Bagshawe et al., 1995; Napier et al., 2000; Francis et al., 2002) have used the bacterial enzyme carboxypeptidase G2 (CP) conjugated to AB7, a monoclonal anticarcinoembryonic antigen (CEA) F(ab)2. This antibody–enzyme conjugate, termed A5CP, has demonstrated feasibility of ADEPT and evidence of therapeutic response in patients with advanced CEA-expressing adenocarcinomas. The use of CP has advantage over human enzymes in that there is no human enzyme with equivalent substrate specificity so that the danger of prodrug activation by host enzyme is avoided. However, the development of human anti-CP antibody (HACA) and human anti-mouse antibody (HAMA) was a serious limitation of ADEPT with A5CP. HACA were observed in 97% and HAMA in 100% after single administration of A5CP (Napier et al., 2000; Francis et al., 2002). Hence, methods of reducing immunogenicity of the antibody–enzyme molecule are required since neutralising antibodies can inactivate therapeutics (Baert et al., 2003) and are potentially detrimental to the patient. Furthermore, protein therapeutics are of increasing importance in the treatment of cancer, so a means to reduce antibody response is likely to be applicable to other therapeutic proteins.

This manuscript explores modification of immunogenic B-cell epitopes as a way to address immunogenicity of protein therapeutics. It was postulated that identification and silencing of epitopes recognised by the human immune system could allow repeated treatment with ADEPT if these epitopes could be disrupted without compromise of enzyme activity. Previously, we developed a system for identifying B-cell epitopes and applied it to identify a discontinuous conformational epitope on CP with the CM79 scFv antibody (CM79-identified epitope; Spencer et al., 2002) (Figure 2). In the current paper we modify the CM79-identified epitope to test our hypothesis.

*Correspondence: Dr A Mayer, Email: a.mayer@ucl.ac.uk
Received 29 December 2003; revised 30 March 2004; accepted 1 April 2004; published online 25 May 2004
The antibody–enzyme molecule chosen for our studies is MFECP, a fusion protein of CP with the single-chain Fv anti-CEA antibody, MFE-23 (Chester et al., 1994; Mayer et al., 2000). MFECP contains the same CP as A5CP but has advantage over A5CP in that MFECP is a recombinant molecule and therefore readily manipulated to disrupt the CM79-identified epitope. Modification of the CM79-identified epitope on the CP moiety of MFECP is proposed as a means of producing a recombinant antibody–enzyme fusion protein which retains activity but lacks the B-cell epitope. This was addressed firstly, by inserting mutations into region 1 (amino acids 157–163) and region 2 (amino acids 412–415) of the CM79-identified epitope and secondly by adding a His-tag to the C-terminus, which comprises part of region 2 (Figure 2). The success of these modifications has been tested by measuring retention of enzyme activity, testing reactivity with immune murine and human sera, investigating potential for repeated therapy in mice and, with one of the constructs, in a clinical trial.

### MATERIALS AND METHODS

**Construction, expression and purification of proteins in Escherichia coli**

Details of plasmid constructs are shown in Figure 3. Construction of pPM331 (encoding MFECP, a recombinant fusion protein of the anti-CEA scFv MFE-23 and CP, an enzyme derived from Variovorax paradoxus, formerly Pseudomonas sp RS 16) has been described previously (Michael et al., 1996). Plasmid pDP161 (encoding MFEdmCP) is identical to MFECP except for a mutation in both regions encoding the discontinuous immunodominant epitope of CP (R162A and G412A) (Spencer et al., 2002). This plasmid was created by isolating a 244 bp SalI/EcoRI fragment from the previously constructed vector carrying G412A (pDP132), and inserting it between the equivalent sites of plasmid pDP130, which carries R162A. This SalI site corresponds to that found at position 1204 of the CP gene (Accession No. M12599), whereas the EcoRI site was created immediately following the TGA stop codon. In relation to Accession No. M12599, the nucleotide substitutions resulting in alanine replacement equate to substitution of CGC (nt 678–680) with GCG (R162A), and substitution of the G at nt 1429 with C (G412A). The pPM331 and pDP161 plasmids were expressed in E. coli TG1 cells and MFECP and MFEdmCP protein were purified on activated CH Sepharose 4B crosslinked to CEA as described previously (Bhatia et al., 2000). The eluted samples were pooled and dialysed overnight against four changes of PBS and 20 × concentrated at 4°C in a stirred cell ultrafiltration system (Amicon, UK) using a YM10 membrane (Millipore, UK). Further purification was carried out by size exclusion chromatography using a 120 ml Superdex 200 column on an automated ÄKTA purification system (Amersham Pharmacia Biotech, UK). Samples were concentrated to approximately 0.15 mg ml⁻¹ and stored at −80°C. Purity and identity were confirmed by sodium dodecylsulfate–polyacrylamide gel electrophoresis (SDS – PAGE) and Western blot, CEA binding was confirmed by enzyme-linked immunosorbent assay (ELISA) (Bhatia et al, 2000).

**Construction, expression and purification of proteins in Pichia pastoris**

MFECP was subcloned into the E. coli/P. pastoris shuttle vector pHICzZB to enable expression in P. pastoris. A His-tag was engineered at the C-terminus of MFECP to facilitate purification.

---

*Figure 1* In the first stage of ADEPT, the intravenously administered antibody–enzyme fusion protein MFECPHis is allowed to localise in the tumour. In the second stage, prodrug ZD2767P, based on a bis-iodo-phenol mustard is given after clearance of enzyme from the circulation. CP cleaves the glutamate moiety to generate the active drug ZD2767D.

*Figure 2* Model of CP showing the discontinuous CM79-identified epitope (region 1 residues 157–163; KEYGVRD coloured in blue, region 2 residues 412–415 coloured in red). The graphic representation was produced with MOLMOL (Koradi et al., 1996).
using immobilised metal affinity chromatography (IMAC). The resultant plasmid construct (pPIC001) is shown in Figure 3. Plasmid pPIC002 is identical to pPIC001 except that it harbours the sequence encoding MFEdmCP instead of MFECP. A His-tag-encoding sequence was added to the MFEdmCP-encoding sequence on pDP161 via PCR. Two primers (Sigma Genosys, UK) were used: a 5′ primer (31 bp) that was designed to amplify the sequence from position 1696, starting 18 bp upstream of the SalI site (MFECP-sense, 5′GAA GCC GCC AAG AAG CTG GTC GAC AAG GCG G) and a 3′ primer (CP-dmXbaHis anti-sense, 3′ACC TGT AAC TGC A) which was complementary from position 1929 to 1947. Additional TGA TGG TGA TGC TTG CCG GCG GCC AGA TCC ATG) which was complementary from position 1929 to 1947.

**Figure 3** Schematic representation of the variants of MFE-CP. Panel A illustrates the genetic constructs of the fusion proteins expressed in _E. coli_ after transfection with pPM331 (MFECP) and pDP161 (MFEdmCP), panel B the fusion proteins expressed in _P. pastoris_ with a C-terminal His-tag after transfection with pPIC001 (MFECPHis) and pPIC002 (MFEdmCPHis).

**A** _E. coli_ expression

- pPM331 (MFECP)
- pDP161 (MFEdmCP)

**B** _P. pastoris_ expression

- pPIC001 (MFECPHis)
- pPIC002 (MFEdmCPHis)

Catalytic activity of CP

Carboxypeptidase G2 cleaves methotrexate (MTX) to give measurable changes in absorbance, which are related to enzyme concentration. This change in absorbance of MTX after CP...
hydrolysis was measured by spectrophotometry at 320 nm (Beckman DU-64 spectrophotometer, Soft Pac Module KINETICS Software Package, Beckman Instruments Ltd, Bucks, UK) as previously described (Minton et al, 1984). Measurements were performed in duplicate, 10 μl of sample were incubated in 1 ml of assay buffer (100 mM Tris-HCl, pH 7.3, 0.2 mM ZnSO4 and 60 mM MTX) at 37°C. Enzyme activity was expressed in units (U), where 1 U is the amount of enzyme required to hydrolyse 1 mmol of MTX per minute at 37°C. Carboxypeptidase G2 (1000 U ml⁻¹) was used as reference standard.

CM79 scFv antibody
The anti-Cp scFv antibody CM79 was expressed in E. coli TG1 cells with a C-terminal His-tag for purification on IMAC as described previously (Spencer et al, 2002). The cell-free supernatant was concentrated and purified on IMAC (Casey et al, 1995) on an automated ÄKTA purification system with a final yield of purified CM79 of approximately 12 mg l⁻¹ culture supernatant. Purity and identity were confirmed by SDS–PAGE and Western blot. A band at the expected molecular weight of 27 kDa consistent with CM79 was detected (data not shown). The purified CM79 antibody was used in a competition ELISA to measure the proportion on immunised mice antibodies that were directed against the CM79-identified epitope (ELISA E). For later experiments, CM79 was biotinylated using the ECL biotinylation kit (Amersham, UK) according to the manufacturer’s instruction. In order to check that CM79 antibody binding was not compromised by biotinylation, the binding of biotinylated and nonbiotinylated CM79 was compared using ELISA (A). Biotinylated CM79 antibody was also used to test disruption of the CM79-identified epitope in ELISA (B) and in competition assays to measure the proportion of human antibodies that were directed against the CM79-identified epitope in ELISA (C).

Murine immunisation studies
Two separate experiments were performed, the first comparing MFeCPHis (endotoxin <0.1 EU ml⁻¹), and MFeDmCPHis (endotoxin 1.1 EU ml⁻¹) and the second experiment comparing MFeCPHis and ASCP (endotoxin <0.1 EU ml⁻¹). ASCP was supplied by Lonza Biologics (UK) for the previous clinical trial (Francis et al, 2002) and consists of an F(ab)² derived from the affinity-purified monoclonal anti-CEA antibody A5B7 covalently linked to CP (Melton et al, 1993). Groups of eight Balb/c mice were injected 4 x intraperitoneally (i.p.) with 50 μg ASCP, MFeCPHis or MFeDmCPHis every 14 days. Mice were bled prior to each injection and 14 days after the final injection. All experiments were performed with ethical committee approval and met the standards of the UK Coordinating Committee on Cancer Research Guidelines for the welfare of animals (Workman et al, 1998). The resulting murine antibody response to CP was assessed using ELISA (D). Murine antibody formation to the CM79-identified epitope was assessed using ELISA (E).

Human immune response
Sera were obtained between 21 and 43 days after treatment with 3000 U m⁻² ASCP (Francis et al, 2002) or 5000 U m⁻² MFeCPHis followed by the prodrg ZD2767P for ADEPT. Both studies were approved by the local research ethics committee and informed consent was obtained from all patients. HACA formation in patients was measured by ELISA (F). Three standard deviations were added to the mean of a pool of pretreatment sera diluted 1/100 to give the cutoff for HACA-positive sera. The proportion of HACA that was directed to the CM79-identified epitope was measured by competition ELISA (G).

ELISAs
The CP-binding capacity of human, murine and scFv antibodies was measured by ELISA. Samples in all ELISAs were applied in duplicate. Blocking to prevent unspecific binding was performed overnight with 5% milk powder in 0.1% Tween 20 in PBS containing 0.02% NaN₃ at 4°C. Incubation times of sera and antibodies were 1 h at room temperature and wash steps consisted of 2 x PBS/0.1% Tween 20 followed by 4 x H₂O. Peroxidase (POX) was detected with a-phenyldiamine (Sigma, UK) in phosphate-citrate buffer with sodium perborate (pH 5; Sigma, UK), the reactions were quenched after 5 min reaction time with 4x HCl and plates were read at 490 nm. Alkaline phosphatase (AP) was detected in all ELISAs with p-nitrophenylphosphate (Sigma, UK) in 0.1 M glycine buffer (1 mM MgCl₂, 1 mM ZnCl₂; pH 10.4) and plates were read at 405 nm on an automated plate reader (Thermo Life Sciences, UK) after 15 min reaction time. Individual ELISA methods varied in order to measure the following:

ELISA (A): CP binding of biotinylated CM79 antibody Binding of biotinylated and nonbiotinylated CM79 antibody was compared by ELISA on CP-coated plates (10 μg ml⁻¹ in carbonate bicarbonate buffer pH 9.2; Sigma, UK). Ten-fold serial dilutions of biotinylated and nonbiotinylated CM79 (6.5 μg ml⁻¹) were added, followed by anti-His antibody (1/500; Qiagen, UK) and POX-labelled sheep anti-mouse antibody (1/1000; Sigma, UK).

ELISA (B): Disruption of CM79-identified epitope Reactivity of fusion proteins with CM79 was tested on plates coated with CEA (1 μg ml⁻¹ in PBS). Fusion proteins (150 ng well⁻¹) were applied prior to biotinylated CM79 (1.3, 0.65 and 0.13 μg ml⁻¹). This was followed by incubation with Extravidin AP (1/5000; Sigma, UK).

ELISA (C): Clinical relevance of CM79-identified epitope Clinical relevance of CM79-identified epitope was tested by comparing the immunoreactivity of HACA positive patients’ sera with MFeCP and MFeDmCP on plates coated with CEA (1 μg ml⁻¹ in PBS) followed by MFeCP or MFeDmCP (0.75 μg ml⁻¹). This was followed by incubation of 10-fold serial dilutions of HACA positive sera after treatment with ASCP and by AP-labelled anti-human γ-chain F(ab) antibody (1/10000; Sigma, UK). Reactivity of individual sera with MFeCP and MFeDmCP was tested on the same plate. Plates were read after 30 min reaction time.

ELISA (D): Murine polyonal anti-CP response Mouse antibodies to CP were measured on plates coated with CP (10 μg ml⁻¹ in carbonate bicarbonate buffer pH 9.2; Sigma, UK). Incubation with mouse sera (diluted 1/100) was followed by AP-labelled anti-mouse Fc antibody (1/2500; Sigma, UK). Ten-fold serial dilutions of the monoclonal anti-CP antibody SB43 (3 μg ml⁻¹) was used as positive control. Plates were read after 30 min reaction time.

ELISA (E): CM79 antibody competition with immunised mouse sera The ability of immunised mouse sera to compete with CM79 antibody was tested on CP-coated plates in a competitive binding assay. Comparison of binding of polyclonal anti-CP antibodies in the presence and absence of CM79 antibody was measured. Mouse sera (diluted 1/100) were applied with and without CM79 antibody (25 μg ml⁻¹), AP labelled anti-mouse Fc antibody (1/2500; Sigma, UK) was used for detection of binding of polyclonal anti-CP antibodies in the presence and absence of CM79 antibody.

ELISA (F): HACA formation in patients The human polyclonal response to CP after treatment with ASCP was measured by ELISA on CP-coated plates as described previously (Sharma et al, 1992). Briefly, HACA formation in patients after MFeCPHis was measured on CP coated plates (10 μg ml⁻¹ in carbonate bicarbonate buffer pH 9.2; Sigma, UK). Incubation of 10-fold serial
ELISA (G): CM79 antibody competition with immunised human sera ELISAs were carried out on (a) CP (10 μg ml⁻¹ in carbonate bicarbonate buffer pH 9.2, Sigma, UK)-coated plates and (b) CEA (1 μg ml⁻¹ in PBS-coated plates followed by ASCP or MFECPHis (150 ng well⁻¹) to ensure that the result was not influenced by a conformational change on CP-coated plates. Patients’ sera (1/100) were spiked with biotinylated CM79 antibody (0.65 μg ml⁻¹). Sera were subsequently applied, in both assays, in 10-fold serial dilutions, followed by incubation with Extravidin AP (1/5000). Inhibition of CM79 antibody binding was taken as evidence that patients’ sera had antibodies directed against the CM79-identified epitope. Binding of biotinylated CM79 antibody in spiked patients’ sera was compared to binding of biotinylated CM79 antibody in the presence of HACA-negative serum.

Statistics
A paired Student’s t-test was used to compare binding of post-treatment sera to MFECP and MFEdmCP and binding of CM79 to fusion proteins. The anti-CP antibody response in the murine immunisation studies and HACA formation in patients after administration of ASCP and MFECPHis was compared by Fisher’s exact test. Wilcoxon signed ranks test was used to compare the murine antibody response to the CM79-identified epitope. An unpaired Student’s t-test assuming equal variances was used for the comparison of the immune response to the CM79-identified epitope after treatment with ASCP and MFEdCPHis.

RESULTS
Modification of the CM79-identified epitope by mutation
The immunogenic CM79-identified B-cell epitope of CP was modified by mutating both of its discontinuous regions on the MFECP fusion protein. Region 1 of the CM79-identified epitope that spans amino acids 157–163 was modified by changing arginine 162 to alanine (R162A), Region 2, which spans amino acids 412–415 at the C-terminus of the molecule was modified by changing glycine 412 to alanine (G412A). The resulting double mutant of the MFECP fusion protein was termed ‘MFECP’. MFEdmCP was expressed in E. coli and purified by affinity chromatography on CEA followed by size exclusion chromatography. MFECP, which contains wild-type CP but is identical to MFEdmCP in all other aspects, was expressed and purified in parallel experiments. Analysis by SDS–PAGE and Western blot confirmed expression of MFEC and MFEdmCP as illustrated in Figure 4 where a major band is shown at 68.5 kDa, the expected molecular weight of the fusion protein. The final yield after purification was low, as only 0.13 mg l⁻¹ of supernatant were recovered for MFECP and 0.1 mg l⁻¹ for MFEdmCP. However, there was no loss of enzymatic activity despite the two mutations, because when the purified proteins were tested for catalytic activity 188 U mg⁻¹ was measured for MFECP and 210 U mg⁻¹ for MFEdmCP.

The CM79-identified epitope is defined by its binding to anti-CP scFv antibody CM79. Successful modification of the epitope is therefore measured by reduction or ablation of binding to CM79 antibody. To test whether this had occurred, 10-fold serial dilutions of the fusion proteins were reacted with CM79 antibody using ELISA on CEA coated wells. The results showed that CM79 antibody binding to MFEdmCP was reduced by 99% compared to MFECP (P = 0.00006, paired Student’s t-test, Table 1). These results indicate successful modification of the CM79-identified epitope by the R162A and G412A mutations because these ablated CM79 antibody binding but did not affect catalytic activity.

Clinical relevance of the CM79-identified epitope
To test whether the modified CM79-identified epitope was recognised by the human immune system MFEdmCP was reacted with serum samples from 12 patients who had made antibodies to CP as a result of receiving ADEPT with ASCP in a previous clinical trial. Serum samples were taken 21–35 days after treatment. For these experiments, MFEdmCP or MFECP was captured on CEA-coated wells and reacted with individual patient’s sera. Results showed that all these sera had lower binding to MFEdmCP than to the unmutated MFECP. The antibody binding in this patient group was reduced by a median of 15.2% (s.d. ± 11.2%) and was statistically significant (P = 0.0002, paired Student’s t-test). The results indicated that the CM79-identified epitope is immunogenic in humans because a significant portion of the human polyclonal antibody response appeared to be directed to this epitope.

Modification of the CM79-identified epitope by addition of a His-tag
Bacterial expression of MFECP and of MFEdmCP gave sufficient material to confirm clinical relevance of the CM79-identified epitope but did not provide a practical means of obtaining large quantities of endotoxin-free fusion proteins for immunogenicity experiments in mice and for clinical trials. This was achieved by expression in the methotrophic yeast P. pastoris under controlled conditions in a fermenter. A C-terminal His-tag was added to facilitate large-scale purification via metal affinity chromatography, bypassing the need for CEA-affinity chromatography. Histagged, P. pastoris expressed, MFECP was termed MFECPHis and His-tagged, P. pastoris expressed, MFEdmCP was termed MFEDmCPHis. These fusion proteins were purified by IMAC. Analysis of purified proteins by SDS–PAGE and Western blot (Figure 4C and D) confirmed expression of MFECPHis and MFEDmCPHis. Both proteins were tested for enzyme activity and the presence of endotoxin. Results showed that the endotoxin content was <0.1 and 1.1 EU ml⁻¹ for MFECPHis and MFEDmCPHis, respectively. The yields obtained with the P. pastoris system were substantially higher than those obtained with E. coli, 11 mg l⁻¹ supernatant for MFECPHis and 12 mg l⁻¹ supernatant for MFEDmCPHis, respectively. The enzyme activity was less than for bacterially expressed fusion proteins, that is, 106 U mg⁻¹ MFECPHis and 42 U mg⁻¹ MFEDmCPHis.

The CM79 binding ELISA was applied to test for the presence of the CM79-identified epitope on MFECPHis and MFEDmCPHis as previously applied to test the untagged E. coli versions of these fusion proteins. Results, shown in Table 1 demonstrated that, as for MFEdmCP, the CM79 antibody binding to MFEDmCPHis was reduced by 99% (s.d. ± 0.45%) compared to MFECP (P = 0.00006, paired Student’s t-test, Table 1). However, MFECPHis was also shown to have reduced reactivity (54%; s.d. ± 2.1%) with the CM79
antibody in comparison to MFECP (P = 0.0006, paired Student’s t-test), although the CM79 site was unmodified. This suggested a masking of the CM79 site by the His-tag and was consistent with the His-tag conferring an independent modification on the CM79 B-cell epitope.

Murine immune response to the CM79-identified epitope

Mouse immunisation experiments were performed to test the hypothesis that the His-tag masked the CM79-identified epitope. In one experiment, the immunogenicity of His-tag modified CP was compared with that of unmodified CP in serum of mice immunised with 50 μg MFECPHis or 50 μg ASCP. In a separate experiment, the immunogenicity of His-tag-modified CP was compared with that of CP that had been modified by His-tag and mutation. In this case, mice were immunised with 50 μg MFECPHis or 50 μg MFEdmCPHis. In both experiments, immunisations were performed every 14 days and mice were bled prior to each injection and after the final injection. A CM79-competition ELISA was designed to measure if anti-CP antibodies formed in response to these immunisations were directed to the CM79-identified epitope. Results of this ELISA indicated that mice immunised with ASCP formed antibodies to the CM79-identified epitope (P = 0.018, Wilcoxon signed ranks test, CP binding of immunised mouse serum in presence and absence of CM79 antibody), whereas mice immunised with MFECPHis or MFEdmCPHis showed no significant response to the CM79-identified epitope in the same test (P = 1.0 and 0.24, respectively). These results indicated not only that modification of the CM79-identified epitope successfully reduced its immunogenicity in mice but that the His-tag was as effective a means of achieving this as the R162A and G412A mutations.

Murine polyclonal antibody response to repeated CP administration

The polyclonal antibody response to CP was measured by ELISA 14 days after each immunising injection of MFECPHis, MFEdmCPHis or ASCP. Results from these experiments, illustrated in Figure 6, show that BALB/c mice immunised with MFECPHis and MFEdmCPHis had no detectable anti-CP antibodies after a single injection, but developed progressively higher levels of antibody after 2, 3, and 4 immunisations with these molecules. Statistical analysis indicated that there was no significant difference in the time taken for development of mouse anti-CP antibodies to MFECPHis and the time taken for development of mouse anti-CP to MFEdmCPHis (P = 0.203, Fisher’s exact test). In contrast to these results, three out of eight mice immunised with ASCP had a detectable anti-CP antibody response after a single dose of ASCP and developed progressively higher levels after further injections (Figure 6). Statistical comparison of mice injected with MFECPHis and ASCP confirmed that injections of MFECPHis can be repeated more times than
with ASCP prior to measurable antibodies to CP ($P = 0.077$, Fisher’s exact test).

Human polyclonal antibody response to CP

Serum of patients after treatment with MFECPhis was tested for polyclonal HACA formation using a validated anti-CP ELISA developed to monitor the ADEPT clinical trial. Results from these experiments showed that only 23% of patients (three out of 13) treated with MFECPhis had detectable HACA after a single administration of MFECPhis (Figure 7), while 97% (36/37) of patients had detectable HACA when treated with ASCP in previous trials (Napier et al., 2000; Francis et al., 2002). Fisher’s exact test confirmed statistical significance ($P = 0.0001$) between the HACA response of these two patient groups.

DISCUSSION

Protein therapeutics form an important part of cancer therapy. Antibodies, cytokines, immunotoxins and enzymes are in routine clinical use and many developing treatments are antibody-based (Carter, 2001; Glennie and van de Winkel, 2003; Hudson and Souriau, 2003). Emergence of these antibody-based therapies has been facilitated by developments in technology, which have largely addressed the limitation of immunogenicity of antibodies by methods such as chimerisation, humanisation and even production of completely human antibodies (Winter and Milstein, 1991; Carter, 2001; Glennie and van de Winkel, 2003). However, in strategies where the antibody arm is used to target bacterial enzymes or toxins, therapy is still limited by development of an antibody response to the effector arm. These targeted therapies have potential to greatly reduce the systemic toxicity of conventional chemotherapy or radiotherapy, but repeated administration is often required for effective therapy. The development of an antibody response involves different cells of the immune system, but the final common pathway involves expansion and differentiation of B-cells with antibody receptors capable of binding to epitopes on the protein therapeutic. Elimination of all immunogenic epitopes from a protein would be a laborious and possibly unachievable task, but a number of approaches have been pursued to circumvent the antibody response by modifying the administered protein to minimise its immunogenicity (Chirino et al., 2004). For example, site-specific pegylation has been successful for an immunotoxin used in cancer therapy (Tsutsumi et al., 2000) and may reduce the immunogenicity of streptavidin that has been used to improve therapeutic ratios in radioimmunotherapy (Chinol et al., 1998). Replacement of foreign sequences by human sequence has reduced, although not entirely eliminated antibody formation to
therapeutic antibodies and cytokines (Richards et al, 1999; Casadevall et al, 2002; Welt et al, 2003). The ability to retain activity while reducing immunogenicity is a key element for success of targeted therapies and is more likely achieved for non-human proteins by mutations in immunogenic epitopes, since this requires minimal change in sequence and structure. In this manuscript, we explore a method to achieving this for MFECp.

MFECp is a multifunctional protein designed for ADEPT, a pretargeted cancer therapy. Reducing immunogenicity of this protein is a particular challenge as the immune response to CP, the bacterial enzyme, which forms part of MFECp, is vigorous. Hence repeated treatment with ADEPT, which is ultimately necessary to achieve effective therapy, has previously only been possible with cyclosporin immunosuppression, which carries the potential of unwanted side effects such as organ toxicity (Sharma et al, 1996). Attempts to overcome this by engineering human carboxypeptidase have been elegant in principal but ineffective in vivo (Wolfe et al, 1999).

We proposed that the immunogenicity of MFECp could best be reduced by modifying a B-cell epitope. B-cell epitopes are often located at a small number of sites on the surface of a protein and, as mentioned above epitope disruption potentially requires only a single amino-acid change. Furthermore, modification of B-cell epitopes is particularly attractive for proteins, where the number of repeat treatments is expected to be limited such as CP for ADEPT. While repeated administration with modified protein may eventually elicit an antibody response to a different set of epitopes, there are at least two different ways in which progressive development of this approach might allow clinically meaningful repetition of treatment in cancer patients with immunogenic proteins. First, modified proteins or totally different proteins with the same function could be used in rotation or sequence so that any antibody response made to a previously used protein would not neutralise a subsequent protein that shares no immunogenic epitopes. Second, is to reduce the ‘danger’ signal provided by protein antigens (Matzinger, 2002). In this situation, a reduction of strongly immunogenic epitopes for either B cells or T_h cells could lead to anergy or tolerance towards minor immunogenic epitopes in a noninflammatory situation. The experience with monoclonal antibodies supports this approach in that murine monoclonal antibodies were strongly immunogenic and led to elimination of the monoclonal antibodies within 14 days in most nonimmunosuppressed patients. Chimerisation of murine monoclonal anti-

bodies still left 15% of the murine variable region sequences present in the chimeric monoclonal antibody, yet there was a dramatic fall in immunogenicity and antibody production. Indeed, clinical experience has failed to show any clinically significant benefit for humanisation in which the residual murine complementarity determining region sequences comprise 7% compared to chimerisation (Baert et al, 2003; Welt et al, 2003). This suggests that the constant region of monoclonal antibodies contain the most strongly immunogenic epitopes and its removal, although not removing all potentially immunogenic epitopes, reduces the ‘danger’ signal sufficiently that they are much less likely to trigger an antibody response.

Identification of B-cell epitopes by hybridoma technology has been laborious in the past, but feasibility has vastly improved due to the availability of a generic method for rapid recognition of B-cell epitopes based on a phage display library of scFv antibodies, surface enhanced laser desorption and ionisation (SELDI) affinity mass spectrometry and bioinformatics tools as described previously by our group (Spencer et al, 2002). The CM79 site, a surface-exposed conformational B-cell epitope comprising the C-terminus and an internal sequence of CP has been identified by this method and we have shown previously that the human antibody response to CP is substantially directed towards this CM79 site. In the current paper, we show that modification of the CM79-identified epitope of CP could be achieved by mutation or by addition of a C-terminal His-tag on the recombinant fusion protein MFECp. Both of these modifications resulted in reduced antibody formation to the CM79-identified epitope. In addition, a delayed antibody response to CP in mouse and a significant reduction of HACA formation in man was seen.

The strategy of mutating B-cell epitopes to reduce immunogenicity has also been applied with success by other workers for staphylokinase (Collen et al, 1996) and L-asparaginase (Moola et al, 1994). This is however, to our knowledge, the first reported instance of successful masking of an immunogenic epitope by addition of a His-tag. His-tags are usually added to proteins for purification purposes and are not widely reported to affect protein function, although Goel et al (2000), have observed that the addition of a His-tag to a scFv antibody appeared to interfere with its antigen-binding. The experimental observations made by these workers were supported by molecular modelling and are consistent with our results that indicate an ability of His-tags to adopt conformational states, which interfere with protein-protein interactions.

Other factors affecting the formation of an antibody response to CP need nevertheless to be considered. Firstly, an immunoreactive T-cell epitope may be involved in the mutated region as recently described for B-cell epitope modified staphylokinase (Warmerdam et al, 2002). However, while mutation may potentially affect a T_h-cell epitope, addition of the C-terminal His-tag is unlikely to have the same effect. Other factors known to affect neutralising antibody formation include the route of administration, dosage regimen, presence of endotoxins and aggregation (Braun et al, 1997). Route of administration and dosage regimen were equivalent for all tested proteins and endotoxins, which are known to increase the immunogenicity of proteins are unlikely to contribute to the differences we observed because all proteins tested in this study had a similar endotoxin content. However, MFECpHis is glycosylated with mannose following expression in P. pastoris and A5CP is not. Glycosylation may mask immunogenic epitopes or affect protein conformation. Also, MFECpHis cleared from circulation within 24h, while A5CP takes several days and MFECpHis was confirmed to be monomeric, while aggregation due to the process of chemical conjugation may contribute to the antibody formation after A5CP. These parameters may contribute to the immune response to the whole molecule and will be investigated in later experiments, but do not explain the lack of the antibody response to the CM79 site.

© 2004 Cancer Research UK British Journal of Cancer (2004) 90(12), 2402–2410
In conclusion, reduced antibody formation to the CM79-identified epitope was observed in mice and men after modification by mutation and addition of a C-terminal His-tag. This was accompanied by a reduced antibody formation to CP, which could allow repeated treatment with ADEPT. Modification of B-cell epitopes appear to be a useful strategy for the reduction of immunogenicity to foreign proteins and may have generic application, in particular for recombinant cancer therapeutics, which are not intended for protracted use.

ACKNOWLEDGEMENTS

We are indebted to Cancer Research UK and the Royal Free Cancer Research Trust for financial support. We thank Robert Boden and Paul Beckett for technical assistance, Dr Richard Morris for statistical advice, Dr Heide Kogelberg for the graphical representation of CP, Professor Robert Hawkins for expert reading of the manuscript and the Cancer Research UK Drug Development Office for support in the clinical trial.

REFERENCES

Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Sherwood RF (1988) A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58: 700 – 703

Bagshawe K, Sharma S, Springer C, Antoniw P (1995) Antibody directed enzyme prodrug therapy: a pilot scale clinical trial. Tumor Target 1: 17 – 30

Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348: 601 – 608

Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW, Read DA, Boxer GM, Michael NP, Begent RHJ (2000) Catalytic activity of an in vivo tumour targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer 85: 571 – 577

Braun A, Kwee L, Labow MA, Alsenz J (1997) Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14: 1472 – 1479

Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1: 118 – 129

Casadevall N, Natal J, Viron B, Kolta A, Kiladijan JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandes J, Varet B, Mayeux P (2002) Pure red-cell aplasia and antilymphoproliferin antibodies in patients treated with recombinant erythropoetin. N Engl J Med 346: 469 – 475

Casey JL, Keep PA, Chester KA, Robson L, Hawkins RE, Begent RHJ (1995) Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J Immunol Methods 179: 105 – 116

Chinol M, Casalini P, Maggioni M, Canevari S, Omodeo ES, Caliceti P, Valsecchi F, BM, Cremaschi M, Chiolerio F, Nardone E, Siccardi AG, Paganelli G (1998) Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 78: 189 – 197

Chirino AJ, Ary ML, Marshall SA (2004) Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9: 82 – 90

Chester KA, Begent RHJ, Robson L, Keep P, Pedley B, Boden JA, Boxer G, Green A, Winter G, Cochet O, Hawkins RE (1994) Phage libraries for generation of clinically useful antibodies. Lancet 343: 455 – 456

Colleen D, Stockx L, Lacroix H, Suy R, Vanderschueren S (1996) Recombinant staphylokinase variants with altered immunoreactivity: IV: Identification of variants with reduced antibody induction and intact potency. Circulation 95: 463 – 472

Francis R, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O’Malley D, Tsiompanou E, Shabakti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RHJ (2000) A Phase 1 trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumors. Br J Cancer 82: 600 – 607

Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8: 503 – 510

Goel A, Colcher D, Koo JS, Booth BJ, Pavlikova G, Batra SK (2000) Relative position of the His-tag effects binding properties of a tumor-associated single-chain Fv construct. Biochim Biophys Acta 1523: 13 – 20

Hudson PJ, Souzaic C (2003) Engineered antibodies. Nat Med 9: 129 – 134

Koradi R, Billeter M, Wüthrich K (1996) MOLMOL: a program for display and analysis of macromolecular structure. J Mol Graph 14: 29 – 32

Matzinger P (2002) The danger model: a renewed sense of self. Science 296: 301 – 305

Mayer A, Tsiompanou E, O’Malley D, Boxer GM, Bathia J, Flynn AA, Chester KA, Davidson BR, Lewis AAM, Winslet MC, Dhillon AP, Hilson AJW, Begent RHJ (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single chain Fv antibody. Clin Cancer Res 6: 1711 – 1719

Melton RG, Boyle JM, Rogers GT, Burke P, Bagshawe KD, Sherwood RF (1993) Optimisation of small scale coupling of AS87 monclonal antibody to carboxypeptidase G2. J Immunol Methods 158: 49 – 56

Michael PM, Chester KA, Melton RG, Robson L, Nicholas W, Bodan JA, Pedley RB, Begent RHJ, Sherwood RF, Minton NP (1996) In vitro and in vivo characterization of a recombinant carboxypeptidase G2: anti-CEA scFv fusion protein. Immunochemistry 2: 47 – 57

Minton NP, Atkinson T, Bruton CJ, Sherwood FR (1988) The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2. Gene 31: 31 – 38

Moola ZB, Scawen MD, Atkinson T, Nicholls D (1994) Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem J 302: 921 – 927

Napier MP, Sharma SK, Springer CJ, Bagshaw KD, Green AJ, Martin J, Stribbling SM, Cussen N, O’Malley D, Begent RHJ (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 6: 765 – 772

Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, Haverty T, Zivin R, Jolliffe L, Bluestone JA (1999) Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res 59: 2096 – 2101

Sharma SK, Bagshaw KD, Melton RG, Sherwood RF (1992) Human immune response to monoclonal antibody–enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 21: 109 – 120

Sharma SK, Bagshawe KD, Melton, Reg RH (1996) Effect of cyclosporin on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT. Transplant Proc 6: 3154 – 3155

Spencer DIR, Robson L, Purdy D, Whitelegg NR, Michael NP, Bhatia J, Sharma S, Rees AR, Minton NP, Begent RHJ, Chester KA (2002) A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics 2: 271 – 279

Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pasan I (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 97: 8548 – 8553

Warmerdam PAM, Vanderklick K, Vanvooderto P, De Smedt H, Plaisance S, De Maeyer M, Collen D (2002) Staphylokinase-specific cell-mediated immunity in humans. J Immunol 168: 155 – 162

Welt S, Ritter G, Williams Jr C, Cohen LS, Jungbluth A, Richards EA, Old LJ, Kemeny NE (2003) Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunother- apy in patients with advanced colorectal cancer. Clin Cancer Res 9: 1347 – 1353

Winter G, Milstein C (1991) Man-made antibodies. Nature 349: 293 – 299

Wolfe LA, Mullin RJ, Laethem R, Blumenkopf TA, Cory M, Miller JF, Keith BR, Humphreys J, Smith GK (1999) Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843. Bioconjug Chem 10: 38 – 48

Workman P, Twentyn P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 77: 1 – 10